Study: Novocure ’ s Optune, drug combo adds months to the lives of GBM patients
Novocure (NSDQ:NVCR) touted today the final analysis of a pivotal Phase III trial that evaluated Optune combined with temozolomide in newly-diagnosed glioblastoma patients.
The analysis, published today in the Journal of the American Medical Association (JAMA), showed that Novocure’s Optune-temozolomide combo extended overall survival and progression-free survival by 37% compared to temozolomide alone.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Novocure’s Optune, drug combo adds months to the lives of GBM patients appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news
More News: American Medical Association (AMA) | Brain | Cancer & Oncology | Clinical Trials | Neurology | Study | Temodar